Pneumococcal Vaccines

Vaccines
11
Pipeline Programs
3
Companies
11
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
4
0
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
7100%
+ 4 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
21-valent pneumococcal conjugate vaccinePhase 4Vaccine1 trial
Active Trials
NCT06271681Not Yet Recruiting45Est. Jun 2027
VaxCyte
VaxCyteSAN CARLOS, CA
8 programs
2
3
3
31 valent pneumococcal conjugate vaccinePhase 3Vaccine1 trial
31-valent pneumococcal conjugate vaccinePhase 3Vaccine1 trial
31-valent pneumococcal conjugate vaccinePhase 3Vaccine1 trial
0.5 mL of the low dose VAX-31Phase 21 trial
0.5 ml dose of 1.1 mcg VAX-24Phase 21 trial
+3 more programs
Active Trials
NCT05266456Completed835Est. Jan 2023
NCT06151288Completed1,015Est. Jul 2024
NCT06720038Active Not Recruiting905Est. Dec 2027
+5 more trials
Inventprise
InventpriseWA - Redmond
2 programs
1
1
IVT PCV-25 Formulation APhase 21 trial
IVT PCV-25Phase 11 trial
Active Trials
NCT05540028CompletedEst. Jul 2023
NCT06077656UnknownEst. May 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
Merck & Co.21-valent pneumococcal conjugate vaccine
VaxCyte31-valent pneumococcal conjugate vaccine
VaxCyte31-valent pneumococcal conjugate vaccine
VaxCyte31 valent pneumococcal conjugate vaccine
VaxCyte0.5 mL of the low dose VAX-31
InventpriseIVT PCV-25 Formulation A
VaxCyte0.5 ml dose of 1.1 mcg VAX-24
VaxCyte24-Valent Pneumococcal Conjugate Vaccine
VaxCyte31 valent pneumococcal conjugate vaccine
VaxCyte24 valent pneumococcal conjugate vaccine
InventpriseIVT PCV-25

Clinical Trials (11)

Total enrollment: 9,829 patients across 11 trials

NCT06271681Merck & Co.21-valent pneumococcal conjugate vaccine

Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans

Start: Jan 2026Est. completion: Jun 202745 patients
Phase 4Not Yet Recruiting
NCT07425392VaxCyte31-valent pneumococcal conjugate vaccine

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

Start: Feb 2026Est. completion: Mar 2027720 patients
Phase 3Recruiting
NCT07365826VaxCyte31-valent pneumococcal conjugate vaccine

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Start: Jan 2026Est. completion: Mar 20271,300 patients
Phase 3Recruiting
NCT07284654VaxCyte31 valent pneumococcal conjugate vaccine

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Start: Dec 2025Est. completion: Jan 20274,000 patients
Phase 3Recruiting
NCT06720038VaxCyte0.5 mL of the low dose VAX-31

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Start: Nov 2024Est. completion: Dec 2027905 patients
Phase 2Active Not Recruiting
NCT06077656InventpriseIVT PCV-25 Formulation A

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Start: Oct 2023Est. completion: May 2024
Phase 2Unknown
NCT05844423VaxCyte0.5 ml dose of 1.1 mcg VAX-24

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Start: Mar 2023Est. completion: Aug 2025802 patients
Phase 2Completed
NCT05297578VaxCyte24-Valent Pneumococcal Conjugate Vaccine

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

Start: Jun 2022Est. completion: Feb 2023207 patients
Phase 2Completed
NCT06151288VaxCyte31 valent pneumococcal conjugate vaccine

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Start: Nov 2023Est. completion: Jul 20241,015 patients
Phase 1/2Completed
NCT05266456VaxCyte24 valent pneumococcal conjugate vaccine

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

Start: Feb 2022Est. completion: Jan 2023835 patients
Phase 1/2Completed
NCT05540028InventpriseIVT PCV-25

Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Start: Sep 2022Est. completion: Jul 2023
Phase 1Completed

Related Jobs in Vaccines

Senior Associate Scientist- Formulations

Pfizer
United States - Massachusetts - Andover
20h ago
$69K - $114K/yr

Professional Health Representative

Pfizer
Qatar - Doha
Yesterday

Sr. Associate Scientist, Upstream Process Development

Pfizer
United States - Massachusetts - Andover
Yesterday
$69K - $114K/yr

Associate Director, Commercial Operations (Trade Operations)

Moderna
USA - New Jersey - Princeton - 5 Vaughn Drive
2d ago
$143K - $257K/yr

Associate Director, Commercial Operations (Trade Operations)

Moderna
Princeton, New Jersey
2d ago
$143K - $257K/yr

Renal / Rare Regional Director – West

Novartis
Field Sales (USA)
2d ago
$204K - $380K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 9,829 patients
Vaccine is the dominant modality (100% of programs)
3 companies competing in this space

Related Indications

Meningococcal Vaccine(5)Vaccination(4)Vaccine Hesitancy(4)Pneumococcal Immunization(3)